
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145761510.1021/acsomega.7b00426ArticleCopper-Promoted Regioselective
Intermolecular Diamination of Ynamides:
Synthesis of Imidazo[1,2-a]pyridines Dwivedi Vikas †Kumar Ravi †‡Sharma Kavita §Sridhar Balasubramanian ∥Reddy Maddi Sridhar *†⊥† Medicinal
& Process Chemistry Division, CSIR-Central
Drug Research Institute, Sector 10, Jankipuram Extn, Sitapur Road, Lucknow 226031, India‡ Academy
of Scientific and Innovative Research, New Delhi 110001, India§ National
Institute of Pharmaceutical Education and Research, Raebareli 229010, India∥X-Ray Crystallography Division and ⊥MCB Division, CSIR-IICT, Tarnaka, Hyderabad 500007, India* E-mail: msreddy@cdri.res.in.19 06 2017 30 06 2017 2 6 2770 2777 10 04 2017 05 06 2017 Copyright © 2017 American Chemical
Society2017American Chemical
SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A facile access to 3-heterosubstituted
(3-oxazolidinonyl/indolyl/phenoxy)
imidazo[1,2-a]pyridines from readily available 2-aminopyridines
and electron-rich (internally activated) alkynes like ynamides/ynamines/ynol
ethers is achieved via Cu(OTf)2-mediated intermolecular
diamination under aerobic conditions. The reaction is highly regioselective,
owing to internal electron bias, and thus led to a single regioisomer
with heterosubstitution at C3.

document-id-old-9ao7b00426document-id-new-14ao-2017-00426jccc-price
==== Body
Introduction
Over the past 2 decades,
ynamides1 have
been featured as one of the utmost versatile building blocks in organic
synthesis, pharmaceuticals, agrochemicals, and material science. This
is mainly because of the embedded nitrogen atom as an electron donor
directly attached to CSP which imposes a strong electronic
bias, rendering levels of chemo-, regio-, and stereo-selectivities.
Moreover, several pharmaceutically and naturally significant structural
motifs that contain nitrogen-embedded heterocycles, such as indoles,2a,2b pyridines,2c−2e and oxazolones,2f,2g were successfully
synthesized from ynamides under metal-catalyzed or metal-free conditions.

The imidazo[1,2-a]pyridine3 skeleton, a class of nitrogen-containing heterocycles composed of
pyridine and imidazole rings, shows numerous biological activities,4 such as antitumor, antiparasitic, antimicrobial,
fungicidal, anti-inflammatory, and hypnotic, and thus is present
in several marketed drugs5 such as alpidem,
zolpidem, necopidem, saripidem, zolimidine, and olprinone. Owing to
such key pharmacological properties, this moiety has earned significant
attention from chemists to develop mild and prolific strategies for
its synthesis.

Therefore, numerous methods have been developed
so far to assemble
imidazo[1,2-a]pyridine from intermolecular heteroannulation
of 2-aminopyridines with various precursors such as α-halo ketones,6 α-diazo ketones,7 carbonyls,8 nitro olefins,9 alkenes,9c and alkynes10a,10b via condensation, multicomponent reaction, aminoxygenation, hydroamination,
oxidative coupling, and C–H functionalization of imidazo[1,2-a]pyridines10c−10f toward diverse substitutions at 2- and 3-positions.

Intermolecular
diamination of alkynes11 has emerged as
a fascinating area of research in current organic
synthesis. It involves heteroannulation with multiple C–N bond
formations, providing rapid access to various medicinally important
heterocycles such as imidazoles,11a quinoxalines,11b,11c and imidazo[1,2-a]pyridines11d,11e employing amidines, 1,2-phenylenediamines, and 2-aminopyridines
as amine partners. Most of the reports used terminal alkynes perhaps
because they, having an obvious steric bias, would not suffer from
regioselectivity issues in the product formation. Few groups successfully
used electronically highly biased internal alkynes such as alkynoates,
haloalkynes, and ynamides, which not only dictated the regioselection
but also introduced a functional group directly on the imidazole ring.
Thus, Jiang et al.12 reported an elegant
copper-catalyzed synthesis of 2-halo-substituted imidazo[1,2-a]pyridines (Scheme 1, eq 1) and Liu et al.13 reported
Cu(II)/Fe(III) cocatalyzed synthesis of imidazo[1,2-a]pyridines with an electron-withdrawing group at the same C2 position
(Scheme 1, eq 2). Furthermore,
gold-catalyzed annulation of 2-aminopyridines with ynamide, an electron-rich
alkyne, also was studied by Davies et al.14 (Scheme 1, eq 3).
Activation of 2-aminopyridine was necessary for this annulation to
be possible, resulting in the same regioisomer with amino group installation
at the C2 position because of gold-catalyzed activation of ynamides
and then attack of activated 2-aminopyridine at α carbon.

Scheme 1 Annulation of Electronically Biased Alkynes with Aminopyridines
As a part of our on-going program
of activation of functionalized
alkynes15 for discovering novel reactions,
herein, we report annulation of inactivated 2-aminopyridines with
ynamides with inverse regioselection for the synthesis of imidazopyridines
with the amino function installed at the C3 position.

Results and Discussion
We commenced our study with ynamide 1a (1 equiv) and
2-aminopyridine 2a (1.5 equiv) with Cu(OTf)2 (20 mol %) as a catalyst under an O2 atmosphere. Delightfully,
the desired imidazo[1,2-a]pyridine, 3a, was obtained, with recovery of more than half of the starting material,
in 12% yield after 6 h (Table 1, entry 1). For further improvement of the yield of 3a, readily available copper catalysts CuCl2, Cu(TFA)2, and Cu(OAc)2 were inspected, but none of them
could do better, whereas Cu(OAc)2 was totally ineffective
(entries 2–4).

Table 1 Optimization Studiesa
s.no.	[Cu]	mol %	additive	solvent	yield %b	conversion %	
1	Cu(OTf)2	20	 	MeCN	12	20	
2	CuCl2	20	 	MeCN	8	12	
3	Cu(OAc)2	20	 	MeCN	n.d.	c	
4	Cu(TFA)2	20	 	MeCN	10	18	
5d	Cu(OTf)2	20	Phl(OAc)2	MeCN	n.d.e	c	
6d	Cu(OTf)2	20	K2S2O8	MeCN	n.d.	c	
7	Cu(OTf)2	100	 	MeCN	62	100	
8	CuCl	100	 	MeCN	48	85	
9	Cul	100	 	MeCN	51	90	
10	CuOTf	100	 	MeCN	55	90	
11f	Cu(OTf)2	100	Pd(TFA)2	MeCN	40	82	
12	Cu(OTf)2	100	 	toluene	50	75	
13	Cu(OTf)2	100	 	dimethylformamide (DMF)	42	52	
14	Cu(OTf)2	100	 	dimethyl sulfoxide
(DMSO)	n.d.	c	
a Reaction conditions: 1 mmol 1a, 3.5 mmol 2a, 100 mol % Cu(OTf)2 in CH3CN (0.1
M) in air for 12 h.

b Isolated
yields.

c Starting material
decomposed.

d Additive (2
equiv).

e n.d. = not detected.

f Additive (20 mol %).

Increasing temperature or prolonged
reaction time was inadequate
to improve the yield. Employing various acid and base additives, such
as K2CO3, Na2CO3, K3PO4, PivOH, pTSA, and NaOAc, proved
to be detrimental to the reaction. Oxidants such as PhI(OAc)2 and K2S2O8 led to the decomposition
of the starting material (Table 1, entries 5–6). Pleasingly, use of equimolar
(100 mol %) Cu(OTf)2 at 60 °C in air furnished the
desired annulated adduct imidazo[1,2-a]pyridine, 3a, in 62% yield (Table 1, entry 7). Other copper(I) salts such as CuCl, CuI,
and CuOTf in similar quantities could not afford the desired product
(Table 1, entries 8–10)
superior to Cu(OTf)2. Employing Pd(TFA)2 as
the cocatalyst also offered a lesser yield than that from Cu(OTf)2 alone (Table 1, entry
11). Other solvents such as toluene and DMF were less effective, whereas
DMSO was totally unproductive (Table 1, entries 12–14), leaving MeCN as the best option
as the solvent.

Summarizing the observations based on optimization
studies, the
optimal condition for intermolecular diamination of ynamide was 1
equiv ynamide, 3.5 equiv 2-aminopyridine, and 100 mol % Cu(OTf)2 in 0.1 M MeCN at 60 °C in air for 12 h.

The scope
of the transformation was investigated under observed
optimal conditions (Table 1). As is evident from Tables 2, 3, and 4, a huge variety of substituted ynamides were converted to the corresponding
imidazo[1,2-a]pyridines in moderate to good yields.
Electron-rich aryl ynamides, such as 4-methyl (1b), 4-ethyl
(1c), 4-t-butyl (1d), and
4-methoxyphenyl ynamide (1e), were successfully converted
to the desired annulated products, 3b–e, but in
moderate yields (54–58%). In contrast, electron-deficient aryl
ynamides showed a relatively better productivity. Thus 3-chloro- (1f), 3-fluoro- (1g), 3,5-difluoro- (1h) phenyl ynamides afforded the products, 3f–h, in 64–73% yields.

Table 2 Synthesis of Various
Imidazo[1,2-a]pyridine Derivativesa
a Reaction conditions: 1 (1 equiv), 2 (3.5 equiv), Cu(OTf)2 (1 equiv),
and solvent (0.1 M).

Table 3 Synthesis of Indole-Based Imidazo[1,2-a]pyridine
Derivativesa
a Reaction Conditions: 4 (1 equiv), 2a (3.5 equiv), Cu(OTf)2 (1 equiv),
and solvent (0.1 M).

Table 4 Extended Scope of Electron-Rich Alkynesa
a Reaction conditions: 6 (1 equiv), 2 (3.5 equiv), Cu(OTf)2 (1 equiv),
and solvent (0.1 M).

Furthermore,
4-chloro- (1i), 4-fluoro- (1j), 4-cyano-
(1k), 4-trifluoromethyl (1l), and 4-methylcarboxyl
(1m) phenyl ynamides could be
annulated with 2-aminopyridines under standard conditions to give
imidazopyridine adducts 3i–m in 52–63%
yields. Next, we examined some variation of substitution on 2-aminopyridines.
Therefore, few commercially available methyl 2-aminopyridines were
chosen for the study. Thus, 4-methyl- and 5-methyl-2-aminopyridines 2n–o reacted smoothly with ynamide 1a under
standard conditions to afford the annulated adducts, 3n-o, in 58–63% yields. Whereas 3-methyl- and 6-methyl-2-aminopyridines 2p–q reacted very slowly (24 h), perhaps due to steric
crowding, but gave the products (3p–q) in acceptable yields (43–48%).

Furthermore, alkylphenyl
and fluorophenyl ynamides were also annulated
with these methyl-substituted 2-aminopyridines with equal ease (3r–u in 51–67%). Next, 5-bromo-2-aminopyridine 2v with ynamide 1a gave 3v in 45%
yield, whereas thiophenyl ynamide 1w with 4-methyl-2-aminopyridine
delivered 3w in 69% yield. A single regioisomer was isolated
in all cases, and the structure of 3u was unambiguously
confirmed by single X-ray crystallography.

At this point, keeping
in mind the pharmacological significance
of indoles and to evaluate the substrate scope with respect to substitution
on the nitrogen terminal of ynamide, we examined some indole-tethered
alkynes anticipating indolyl imidazo[1,2-a]pyridines.
Delightfully, the readily synthesizable ynamines based on methyl indole-2-carboxylate
(4a), ethyl indole-2-carboxylate (4b), and
3-acetyl indole (4c) were transformed through the reaction
successfully to deliver the corresponding products (5a–5c) in 59–71% yields. The structure of 5b was confirmed by X-ray crystallography study.

After
successfully testing the title reaction on ynamides/ynamines,
we turned our focus to test it on their oxygen counterparts, that
is, ynol ethers. Applying optimized conditions with ynol ether 6a, delightfully, the desired product, 7a, was
afforded in 68% yield. 3- and 5-Methyl-substituted 2-aminopyridines
(7b in 56% and 7c in 58%) and tolyl-ynol
ether (7d, 64%) were also transformed to the anticipated
products with equal ease.

On the basis of previous reports,
a putative mechanism of this
copper-mediated diamination of ynamides with 2-aminopyridines is proposed
in Scheme 2. It is
proposed that the reaction starts with coordination of the copper
salt with the pyridyl nitrogen and ynamide while forming a covalent
bond with the amino group of 2-aminopyridine, as indicated in intermediate A. This A upon ynamide N-assisted nucleophilic
displacement leads to Cu-ketenimine complex B, which
after intramolecular pyridine attack on the electrophilic central
carbon forms a 6-membered cuprous metellacycle, C. Reductive
elimination of Cu(0) from C led to the final product.

Scheme 2 Probable Reaction Mechanism
In conclusion, we have demonstrated a protocol for the
regioselective
annulation of electron-rich alkynes, ynamides/ynamines and ynol ethers,
with readily available 2-aminopyridines to access the biologically
interesting imidazo[1,2-a]pyridines with 3-heterosubstitution.
The reaction is mediated by Cu(OTf)2 and is conducted in
open air. The mechanism is postulated to involve at the end the reduction of Cu(II)
to Cu(0); hence, it is required in stoichiometric amount.

Experimental
Section
General Information
All reagents and solvents were
purchased from commercial sources and used without purification. NMR
spectra were recorded with a 400 or 500 MHz spectrometer for 1H NMR and with a 100 or 125 MHz spectrometer for 13C NMR spectroscopy. Chemical shifts are reported relative to the
residual signals of tetramethylsilane in CDCl3 or deuterated
solvent CDCl3 for 1H and 13C NMR
spectroscopy. High-resolution mass spectrometry (HRMS) spectra were
recorded using a quadrupole time-of-flight mass spectrometer. Column
chromatography was performed with silica gel (230–400 mesh)
as the stationary phase. All reactions were monitored using thin-layer
chromatography (TLC).

General Procedure for the Synthesis of 3/5/7
A mixture of ynamide/ynamine/ynol
ether substrate 1/4/6 (1.0
mmol), 2-aminopyridines 2 (3.5 mmol), and Cu(OTf)2 (1.0 mmol) was added in 0.1 M CH3CN at 60 °C for 12–24
h. Upon completion of the reaction as indicated by TLC, the reaction
mixture was concentrated under reduced pressure and the residue was
purified by column chromatography.

Characteristic Data of
Final Compounds
3-(2-Phenylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3a)
Off-white solid; mp 223–225 °C; Rf = 0.46 (70% ethyl acetate/hexanes);
yield = 173 mg (62%); 1H NMR (400 MHz, CDCl3): δ 7.94 (d, J = 6.8 Hz, 1H), 7.88 (d, J = 7.1 Hz, 2H), 7.67 (d, J = 9.0 Hz, 1H),
7.50 (t, J = 7.5 Hz, 2H), 7.41 (t, J = 7.3 Hz, 1H), 7.33–7.25 (m, 1H), 6.95–6.88 (m, 1H),
4.64 (t, J = 7.9 Hz, 2H), 3.87 (t, J = 7.9 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.6, 143.3, 140.4, 132.8, 128.9, 128.5, 127.2, 125.6,
122.4, 118.0, 114.0, 112.9, 63.2, 45.3 ppm; IR (KBr) ν 3583,
1756, 1412, 1252, 1081, 665 cm–1; HRMS (electrospray
ionization (ESI)) calcd for C16H14N3O2 [M + H] 280.1086 found 280.1074.

3-(2-(p-Tolyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3b)
Off-white
solid; mp 110–112 °C; Rf = 0.46 (70% ethyl acetate/hexanes); yield = 170 mg (58%); 1H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 6.7 Hz, 1H), 7.77 (d, J = 8.0 Hz, 2H),
7.67 (d, J = 9.0 Hz, 1H), 7.31 (d, J = 8.1 Hz, 3H), 6.92 (t, J = 6.6 Hz, 1H), 4.65 (t, J = 7.9 Hz, 2H), 3.88 (t, J = 7.9 Hz, 2H),
2.43 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3):
δ 156.6, 143.3, 140.6, 138.7, 129.9, 129.6, 127.1, 125.5, 122.3,
118.0, 112.8, 63.2, 45.3, 21.3 ppm; IR (KBr) ν 3665, 2305, 2037,
1486, 1248, 1080, 666 cm–1; HRMS (ESI) calcd for
C17H16N3O2 [M + H] 294.1243
found 294.1238.

3-(2-(4-Ethylphenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3c)
White solid; mp 178–179 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 169 mg (55%); 1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 6.6 Hz, 1H), 7.77 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 9.0 Hz, 1H),
7.38–7.17 (m, 3H), 6.88 (t, J = 6.6 Hz, 1H),
4.63 (t, J = 7.9 Hz, 2H), 3.86 (t, J = 7.9 Hz, 2H), 2.70 (q, J = 7.6 Hz, 2H), 1.27 (t, J = 7.6 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.6, 144.9, 143.4, 140.7, 130.2, 128.5, 127.3,
125.6, 122.4, 118.2, 113.8, 113.0, 63.3, 45.5, 28.8, 15.4 ppm; IR
(KBr) ν 3583, 3392, 1755, 1390, 1084, 665 cm–1; HRMS (ESI) calcd for C18H18N3O2 [M + H] 308.1399 found 308.1390.

3-(2-(4-(tert-Butyl)phenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3d)
Brown solid; mp 114–116 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 168
mg (56%); 1H NMR (400 MHz, CDCl3): δ 7.92
(d, J = 6.6 Hz, 1H), 7.82 (d, J =
8.2 Hz, 2H), 7.66 (d, J = 9.0 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.36–7.20 (m, 1H), 6.90 (t, J = 6.7 Hz, 1H), 4.66 (t, J = 7.9 Hz, 2H),
3.90 (t, J = 7.9 Hz, 2H), 1.38 (s, 9H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.5, 151.6,
143.3, 140.4, 129.8, 126.8, 125.8, 125.4, 122.3, 118.0, 113.7, 112.8,
63.2, 45.3, 34.7, 31.2 ppm; IR (KBr) ν 3211, 1751, 1628, 1416,
1081, 843, 637 cm–1; HRMS (ESI) calcd for C20H22N3O2 [M + H] 336.1712
found 336.1694.

3-(2-(4-Methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3e)
White solid; mp 114–116 °C; Rf = 0.44 (70% ethyl acetate/hexanes);
yield = 173 mg (56%); 1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 6.6 Hz, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 9.0 Hz, 1H),
7.32–7.21 (m, 1H), 7.01 (d, J = 8.6 Hz, 2H),
6.88 (t, J = 6.6 Hz, 1H), 4.62 (t, J = 7.9 Hz, 2H), 3.86 (s, 5H) ppm; 13C NMR (100 MHz, CDCl3): δ 160.0, 156.7, 143.3, 140.4, 128.7, 125.7, 125.2,
122.4, 117.9, 114.5, 113.4, 113.0, 63.3, 55.4, 45.4 ppm; IR (KBr)
ν 3012, 2840, 1759, 1613, 1512, 1302, 1146, 754, 664 cm–1; HRMS (ESI) calcd for C17H16N3O3 [M + H] 310.1192 found 310.1176.

3-(2-(3-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3f)
Light yellow solid; mp 116–118 °C; Rf = 0.44 (70% ethyl acetate/hexanes);
yield = 200 mg (64%); 1H NMR (400 MHz, CDCl3): δ 7.99–7.84 (m, 2H), 7.76–7.61 (m, 2H), 7.46–7.33
(m, 2H), 7.33–7.27 (m, 1H), 6.92 (t, J = 6.6
Hz, 1H), 4.66 (t, J = 7.9 Hz, 2H), 3.88 (t, J = 7.9 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.4, 143.4, 139.0, 134.9, 134.6, 130.2, 128.5,
127.3, 126.0, 125.1, 122.4, 118.2, 114.3, 113.2, 63.3, 45.4 ppm; IR
(KBr) ν 3020, 2960, 1762, 1579, 1481, 1357, 1215, 1081, 755,
664 cm–1; HRMS (ESI) calcd for C16H13ClN3O2 [M + H] 314.0696 found 314.0690.

3-(2-(3-Fluorophenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3g)
Brown solid; mp 106–108 °C; Rf = 0.44 (70% ethyl acetate/hexanes);
yield = 205 mg (69%); 1H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 6.7 Hz, 1H), 7.74–7.58
(m, 3H), 7.50–7.41 (m, 1H), 7.35–7.26 (m, 1H), 7.16–7.06
(m, 1H), 6.94 (t, J = 6.7 Hz, 1H), 4.68 (t, J = 7.9 Hz, 2H), 3.91 (t, J = 7.9 Hz, 2H)
ppm; 13C NMR (100 MHz, CDCl3): δ 163.2
(d, J = 246.0 Hz), 156.4, 143.3, 139.3, 135.0 (d, J = 8.0 Hz), 130.5 (d, J = 8.2 Hz), 125.9,
122.7, 122.4, 118.2, 115.4 (d, J = 21.0 Hz), 114.2
(d, J = 22.8 Hz), 113.2, 63.2, 45.4 ppm; IR (KBr)
ν 3018, 1759, 1617, 1441, 1277, 1079, 664 cm–1; HRMS (ESI) calcd for C16H13FN3O2 [M + H] 298.0992 found 298.0981.

3-(2-(3,5-Difluorophenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3h)
Off-white solid; mp 154–156 °C; Rf = 0.44 (70% ethyl acetate/hexanes);
yield = 230 mg (73%); 1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 6.8 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.45–7.38 (m, 2H), 7.35–7.27
(m, 1H), 6.93 (t, J = 6.7 Hz, 1H), 6.88 (m, 1H),
4.68 (t, J = 7.9 Hz, 2H), 3.91 (t, J = 7.9 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 163.3 (dd, J = 248.0, 12.7 Hz), 156.3,
143.3, 138.2, 136.0 (t, J = 10.1 Hz), 126.2, 122.4,
118.3, 114.5, 113.4, 109.9 (dd, J = 19.2, 7.4 Hz),
103.8 (t, J = 25.3 Hz), 63.2, 45.4 ppm; IR (KBr)
ν 3214, 1657, 1521, 1400, 962, 664 cm–1; HRMS
(ESI) calcd for C16H12F2N3O2 [M + H] 316.0898 found 316.0892.

3-(2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3i)
Off-white solid; mp 56–58 °C; Rf = 0.42 (70% ethyl acetate/hexanes);
yield = 188 mg (60%); 1H NMR (400 MHz, CDCl3): δ 7.91 (d, J = 6.8 Hz, 1H), 7.80 (dd, J = 6.7, 1.8 Hz, 2H), 7.66 (d, J = 9.0
Hz, 1H), 7.47–7.43 (m, 2H), 7.32–7.27 (m, 1H), 6.95–6.90
(m, 1H), 4.65 (t, J = 7.9 Hz, 2H), 3.86 (t, J = 7.9 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.4, 134.5, 131.3, 129.2, 128.5, 125.9, 122.3,
118.2, 113.2, 63.2, 45.4 ppm; IR (KBr) ν 3021, 2401, 1630, 1417,
1030, 928, 667 cm–1; HRMS (ESI) calcd for C16H13ClN3O2 [M + H] 314.0696
found 314.0688.

3-(2-(4-Fluorophenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3j)
White solid; mp 144–146 °C; Rf = 0.44 (70% ethyl acetate/hexanes);
yield = 178 mg (60%); 1H NMR (400 MHz, CDCl3): δ 7.92 (d, J = 6.6 Hz, 1H), 7.90–7.79
(m, 2H), 7.66 (d, J = 9.0 Hz, 1H), 7.33–7.25
(m, 1H), 7.18 (t, J = 8.5 Hz, 2H), 6.91 (t, J = 6.6 Hz, 1H), 4.65 (t, J = 7.9 Hz, 2H),
3.86 (t, J = 7.9 Hz, 2H) ppm; 13C NMR
(100 MHz, CDCl3): δ 162.9 (d, J =
248.0 Hz), 156.5, 143.3, 139.8, 129.1 (d, J = 8.2
Hz), 125.8, 122.3, 118.1, 115.9 (d, J = 21.5 Hz),
113.7, 113.0, 63.2, 45.4 ppm; IR (KBr) ν 3017, 2961, 1758, 1634,
976, 664 cm–1; HRMS (ESI) calcd for C16H13FN3O2 [M + H] 298.0992 found
298.0985.

4-(3-(2-Oxooxazolidin-3-yl)imidazo[1,2-a]pyridin-2-yl)benzonitrile
(3k)
White solid; mp 145–147 °C; Rf = 0.44 (70% ethyl acetate/hexanes);
yield = 191 mg (63%); 1H NMR (400 MHz, CDCl3): δ 8.12–7.91 (m, 3H), 7.79 (d, J =
8.1 Hz, 2H), 7.69 (d, J = 9.2 Hz, 1H), 7.45–7.32
(m, 1H), 6.99 (t, J = 6.6 Hz, 1H), 4.71 (t, J = 7.9 Hz, 2H), 3.92 (t, J = 7.9 Hz, 2H)
ppm; 13C NMR (100 MHz, CDCl3): δ 156.5,
144.1, 137.4, 132.9, 127.8, 126.6, 122.6, 118.8, 118.5, 113.8, 112.1,
63.4, 45.7 ppm; IR (KBr) ν 3321, 1695, 1520, 1479, 1021, 660
cm–1; HRMS (ESI) calcd for C17H13N4O2 [M + H] 305.1039 found 305.1026.

3-(2-(4-(Trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one (3l)
Off-white
solid; mp 199–201 °C; Rf = 0.40 (70% ethyl acetate/hexanes); yield = 180 mg (52%); 1H NMR (400 MHz, CDCl3): δ 7.99 (d, J = 7.9 Hz, 2H), 7.93 (d, J = 6.4 Hz, 1H),
7.73 (d, J = 7.9 Hz, 2H), 7.67 (d, J = 8.9 Hz, 1H), 7.37–7.28 (m, 1H), 6.93 (t, J = 6.6 Hz, 1H), 4.66 (t, J = 7.9 Hz, 2H), 3.87 (t, J = 7.9 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.5, 143.5, 137.7 (d, J = 260
Hz), 130.2 (q, J = 32 Hz), 127.5, 126.2, 125.9, 125.3,
122.8, 122.5, 118.3, 114.8, 113.4, 63.3, 45.3 ppm; IR (KBr) ν
3394, 1622, 1414, 1246, 1165, 1083, 976, 755 cm–1; HRMS (ESI) calcd for C17H13F3N3O2 [M + H] 348.0960 found 348.0946.

Methyl 4-(3-(2-oxooxazolidin-3-yl)imidazo[1,2-a]pyridin-2-yl)benzoate (3m)
White
solid; mp
154–156 °C; Rf = 0.46 (70% ethyl acetate/hexanes); yield = 199 mg (59%); 1H NMR (400 MHz, CDCl3): δ 8.17 (d, J = 8.4 Hz, 2H), 8.01–7.92 (m, 3H), 7.70 (d, J = 9.0 Hz, 1H), 7.38–7.31 (m, 1H), 6.97 (t, J = 6.8 Hz, 1H), 4.68 (t, J = 7.9 Hz, 2H), 3.97 (s,
3H), 3.90 (t, J = 7.9 Hz, 2H) ppm; 13C
NMR (100 MHz, CDCl3): δ 166.9, 160.0, 156.5, 130.3,
130.1, 127.2, 126.2, 122.6, 118.5, 113.5, 63.4, 52.3, 45.6 ppm; IR
(KBr) ν 3583, 2921, 1611, 1358, 1280, 756 cm–1; HRMS (ESI) calcd for C18H16N3O4 [M + H] 338.1141 found 338.1127.

3-(7-Methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3n)
Off-white solid; mp 163–165 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 184 mg (63%); 1H NMR (400 MHz, CDCl3): δ 7.84 (d, J = 7.3 Hz, 2H), 7.78 (d, J = 6.9 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H),
7.42–7.33 (m, 2H), 6.71 (d, J = 6.0 Hz, 1H),
4.61 (t, J = 7.9 Hz, 2H), 3.83 (t, J = 7.9 Hz, 2H), 2.42 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.7, 143.9, 140.2, 136.9, 133.0, 129.0, 128.5,
127.3, 121.7, 116.6, 115.7, 113.6, 63.3, 45.6, 21.5 ppm; IR (KBr)
ν 3321, 1583, 1456, 1387, 1120, 664 cm–1;
HRMS (ESI) calcd for C17H16N3O2 [M + H] 294.1243 found 294.1238.

3-(6-Methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3o)
Off-white solid; mp 154–156 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 167 mg (57%); 1H NMR (400 MHz, CDCl3): δ 7.96–7.72 (m, 3H), 7.55–7.31 (m, 4H), 6.71
(d, J = 5.9 Hz, 1H), 4.60 (t, J =
7.9 Hz, 2H), 3.83 (t, J = 7.9 Hz, 2H), 2.41 (s, 3H)
ppm; 13C NMR (100 MHz, CDCl3): δ 156.7,
136.9, 129.0, 128.5, 127.3, 127.2, 123.0, 121.7, 120.1, 117.5, 116.5,
115.7, 63.3, 45.5, 21.4 ppm; IR (KBr) ν 3214, 2851, 1721, 1547,
1394, 953, 664 cm–1; HRMS (ESI) calcd for C17H16N3O2 [M + H] 294.1243
found 294.1240.

3-(8-Methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3p)
Off-white solid; mp105–107 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 170 mg (58%); 1H NMR (400 MHz, CDCl3): δ 7.92–7.82 (m, 2H), 7.78 (d, J =
6.7 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.42–7.32
(m, 1H), 7.06 (d, J = 6.8 Hz, 1H), 6.80 (t, J = 6.8 Hz, 1H), 4.60 (t, J = 7.9 Hz, 2H),
3.83 (t, J = 7.9 Hz, 2H), 2.65 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.7, 143.8,
140.2, 133.2, 129.0, 128.4, 128.3, 127.5, 124.4, 120.2, 114.4, 113.1,
63.2, 45.6, 16.7 ppm; IR (KBr) ν 3131, 2965, 1860, 1774, 1091,
931, 666 cm–1; HRMS (ESI) calcd for C17H16N3O2 [M + H] 294.1243 found 294.1222.

3-(5-Methyl-2-phenylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3q)
Off-white solid; mp 154–156 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 146 mg (50%); 1H NMR (400 MHz, CDCl3): δ 7.87–7.76 (m, 2H), 7.59–7.45 (m, 3H), 7.45–7.37
(m, 1H), 7.18 (dd, J = 8.9, 6.9 Hz, 1H), 6.61 (d, J = 6.8 Hz, 1H), 4.63–4.41(m, 2H), 3.89–3.66(m,
2H), 2.79(s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 158.5, 135.2, 133.0, 129.5, 129.0, 128.7, 128.3, 127.7,
126.1, 116.3, 114.5, 62.7, 48.5, 18.3 ppm; IR (KBr) ν 3011,
1854, 1601, 1482, 1125, 633 cm–1; HRMS (ESI) calcd
for C17H16N3O2 [M + H]
294.1243 found 294.1240.

3-(2-(4-Butylphenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3r)
Off-white solid; mp 218–220 °C; Rf = 0.48 (70% ethyl acetate/hexanes);
yield = 185 mg (53%); 1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 8.0 Hz, 2H),7.67 (s, 1H),
7.53 (d, J = 9.1 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 9.0 Hz, 1H), 4.63 (t, J = 7.9 Hz, 2H), 3.85 (t, J = 7.9 Hz, 2H),
2.65 (t, J = 7.8 Hz, 2H), 2.35 (s, 3H), 1.67–1.60
(m, 2H), 1.42–1.35 (m, 2H), 0.94 (t, J = 7.3
Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ
151.8, 138.5, 126.1, 125.5, 124.2, 123.9, 122.2, 117.9, 115.2, 112.6,
58.4, 40.6, 30.7, 28.7, 17.6, 13.5, 9.2 ppm; IR (KBr) ν 3014,
2130, 1692, 1300, 903, 651 cm–1; HRMS (ESI) calcd
for C21H24N3O2 [M + H]
350.1869 found 350.1864.

3-(2-(4-(tert-Butyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one (3s)
Off-white solid; mp 231–233 °C; Rf = 0.48 (70% ethyl acetate/hexanes); yield
= 188 mg (54%); 1H NMR (400 MHz, CDCl3): δ
7.82–7.74 (m, 3H), 7.47 (d, J = 8.4 Hz, 2H),
7.39 (s, 1H), 6.71 (d, J = 6.9 Hz, 1H), 4.63 (t, J = 7.9 Hz, 2H), 3.87 (t, J = 7.9 Hz, 2H),
2.41 (s, 3H), 1.35 (s, 9H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.6, 151.4, 143.7, 140.0, 136.6, 129.9, 126.7,
125.8, 121.5, 116.2, 115.4, 113.2, 63.1, 45.4, 34.6, 31.2, 21.3 ppm;
IR (KBr) ν 3380, 2033, 1487, 1312, 943, 681 cm–1; HRMS (ESI) calcd for C21H24N3O2 [M + H] 350.1869 found 350.1852.

3-(2-(3-Fluorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one (3t)
Off-white
solid; mp 110–112 °C; Rf = 0.44 (70% ethyl acetate/hexanes); yield = 208 mg (67%); 1H NMR (400 MHz, CDCl3): δ 7.69 (s, 1H), 7.66–7.59
(m, 2H), 7.56 (d, J = 9.2 Hz, 1H), 7.49–7.39
(m, 1H), 7.15 (d, J = 9.2 Hz, 1H), 7.12–7.04
(m, 1H), 4.68 (t, J = 7.9 Hz, 2H), 3.89 (t, J = 7.9 Hz, 2H), 2.37 (s, 3H) ppm; 13C NMR (100
MHz, CDCl3): δ 163.1 (d, J = 246.1
Hz), 156.5, 142.4, 139.0, 135.2 (d, J = 8.2 Hz),
130.4 (d, J = 8.2 Hz), 129.1, 123.2, 122.6 (d, J = 2.7 Hz), 120.0, 117.4, 115.2 (d, J =
21.1 Hz), 114.0 (d, J = 23.0 Hz), 63.2, 45.4, 18.2
ppm; IR (KBr) ν 3087, 2471, 1590, 1431, 943, 837, 681 cm–1; HRMS (ESI) calcd for C17H15FN3O2 [M + H] 312.1148 found 312.1144.

3-(2-(4-Fluorophenyl)-8-methylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one (3u)
White solid;
mp 154–156 °C; Rf = 0.44 (70% ethyl acetate/hexanes); yield = 205 mg (66%); 1H NMR (400 MHz, CDCl3): δ 7.89–7.80
(m, 2H), 7.77 (d, J = 6.6 Hz, 1H), 7.20–7.12
(m, 2H), 7.10–7.03 (m, 1H), 6.81 (t, J = 6.6
Hz, 1H), 4.61 (t, J = 7.9 Hz, 2H), 3.82 (t, J = 7.9 Hz, 2H), 2.64 (s, 3H) ppm; 13C NMR (100
MHz, CDCl3): δ 163.0 (d, J = 249.5
Hz), 156.7, 143.8, 139.5, 129.4 (d, J = 8.5 Hz),
128.3, 124.6, 120.2, 116.0 (d, J = 21.5 Hz), 113.3,
63.2, 45.6, 16.7 ppm; IR (KBr) ν 3485, 2928, 1668, 1217, 930,
824, 637 cm–1; HRMS (ESI) calcd for C17H15FN3O2 [M + H] 312.1148 found
312.1136.

3-(6-Bromo-2-phenylimidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3v)
White solid; mp 204–206 °C; Rf = 0.40 (70% ethyl acetate/hexanes);
yield = 161 mg (45%); 1H NMR (400 MHz, CDCl3): δ 8.05 (s, 1H), 7.82 (d, J = 7.3 Hz, 2H),
7.55 (d, J = 9.4 Hz, 1H), 7.48 (t, J = 7.3 Hz, 2H), 7.44-7.37 (m, 1H), 7.34 (d, J =
9.4 Hz, 1H), 4.65 (t, J = 7.9 Hz, 2H), 3.85 (t, J = 7.9 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.4, 141.7, 141.1, 132.3, 129.0 (t, J = 18.0 Hz), 127.2, 122.6, 118.7, 107.9, 63.3, 45.3 ppm; IR (KBr)
ν 3424, 2981, 1579, 1414, 1146, 1088, 918, 664 cm–1; HRMS (ESI) calcd for C16H13BrN3O2 [M + H] 358.0191 found 358.0179.

3-(7-Methyl-2-(thiophen-3-yl)imidazo[1,2-a]pyridin-3-yl)oxazolidin-2-one
(3w)
Brown solid; mp 120–122 °C; Rf = 0.50 (70% ethyl acetate/hexanes);
yield = 206 mg (69%); 1H NMR (400 MHz, CDCl3): δ 7.81 (d, J = 6.9 Hz, 1H), 7.76 (s, 1H),
7.55 (d, J = 4.8 Hz, 1H), 7.47–7.42 (m, 1H),
7.40 (s, 1H), 6.75 (d, J = 6.8 Hz, 1H), 4.68 (t, J = 7.9 Hz, 2H), 3.92 (t, J = 7.9 Hz, 2H),
2.44 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3):
δ 156.7, 143.8, 137.2, 136.7, 133.9, 126.6, 126.3, 123.3, 121.6,
116.3, 115.8, 63.3, 45.6, 21.5 ppm; IR (KBr) ν 3324, 1579, 1502,
1354, 1146, 832, 649 cm–1; HRMS (ESI) calcd for
C15H14N3O2S [M + H] 300.0807
found 300.0792.

Methyl 1-(2-phenylimidazo[1,2-a]pyridin-3-yl)-1H-indole-2-carboxylate
(5a)
Yellow solid; mp 157–159 °C; Rf = 0.50 (40% ethyl acetate/hexanes);
yield = 246 mg (67%); 1H NMR (400 MHz, CDCl3): δ 7.87–7.82 (m, 1H), 7.76 (d, J =
9.1 Hz, 1H), 7.68 (s, 1H), 7.46–7.38 (m, 3H), 7.33–7.27
(m, 3H), 7.25–7.17 (m, 3H), 7.00–6.89 (m, 1H), 6.78
(t, J = 6.6 Hz, 1H), 3.68 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 160.8, 143.4, 140.4, 139.9,
132.5, 128.9, 128.7, 128.1, 127.0, 126.9, 126.5, 125.6, 123.0, 122.7,
122.5, 117.9, 114.1, 112.8, 111.4, 52.0 ppm; IR (KBr) ν 1634,
1580, 1088, 940, 831, 666 cm–1; HRMS (ESI) calcd
for C23H18N3O2 [M + H]
368.1399 found 368.1386.

Ethyl 1-(2-phenylimidazo[1,2-a]pyridin-3-yl)-1H-indole-2-carboxylate
(5b)
Yellow solid; mp 151–153 °C; Rf = 0.46 (40% ethyl acetate/hexanes);
yield = 225 mg (59%); 1H NMR (400 MHz, CDCl3): δ 7.84–7.75 (m, 1H), 7.72 (d, J =
9.1 Hz, 1H), 7.67 (s, 1H), 7.45–7.32 (m, 3H), 7.32–7.20
(m, 3H), 7.20–7.10 (m, 3H), 6.97–6.83 (m, 1H), 6.83–6.69
(m, 1H), 4.07–3.98 (m, 2H), 0.91 (t, J = 7.1
Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ
160.4, 143.2, 140.3, 139.8, 132.5, 129.5, 128.7, 128.1, 127.1, 126.9,
126.5, 125.5, 122.9, 122.6, 122.6, 117.9, 114.2, 112.8, 111.4, 60.9,
13.7 ppm; IR (KBr) ν 1764, 1593, 1163, 934, 743, 646 cm–1; HRMS (ESI) calcd for C24H20N3O2 [M + H] 382.1556 found 382.1538.

1-(1-(2-Phenylimidazo[1,2-a]pyridin-3-yl)-1H-indol-3-yl)ethan-1-one
(5c)
Light yellow solid; mp 270–272 °C; Rf = 0.46 (40% ethyl acetate/hexanes);
yield = 249 mg (71%); 1H NMR (400 MHz, CDCl3): δ 8.55 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H),
7.76 (d, J = 9.1 Hz, 1H), 7.56–7.50 (m, 2H),
7.46–7.38 (m, 2H), 7.37–7.32 (m, 1H), 7.31–7.26
(m, 4H), 6.98 (d, J = 8.2 Hz, 1H), 6.82 (t, J = 6.7 Hz, 1H), 2.54 (s, 3H) ppm; 13C NMR (100
MHz, CDCl3): δ 193.3, 143.4, 140.4, 137.5, 135.4,
131.7, 128.8, 128.6, 126.6, 126.3, 126.2, 125.0, 124.0, 123.2, 122.2,
120.9, 118.1, 114.3, 113.4, 110.5, 27.7 ppm; IR (KBr) ν 1698,
1491, 1110, 936, 827, 681 cm–1; HRMS (ESI) calcd
for C23H18N3O [M + H] 352.1450 found
352.1431.

3-Phenoxy-2-phenylimidazo[1,2-a]pyridine (7a)
White solid; mp 111–113
°C; Rf = 0.48 (30%
ethyl acetate/hexanes);
yield = 194 mg (68%); 1H NMR (400 MHz, CDCl3): δ 8.11–7.98 (m, 2H), 7.73 (d, J =
6.6 Hz, 1H), 7.62 (d, J = 9.1 Hz, 1H), 7.42–7.34
(m, 2H), 7.33–7.26 (m, 3H), 7.22–7.14 (m,1H), 7.09 (t, J = 7.4 Hz, 1H), 6.99–6.91 (m, 2H), 6.79–6.69
(m, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ
156.2, 140.0, 132.6, 131.3, 130.3, 130.1, 128.7, 127.8, 126.6, 124.4,
123.8, 121.7, 118.0, 115.1, 112.4 ppm; IR (KBr) ν 1587, 1447,
1362, 1274, 1072, 607 cm–1; HRMS (ESI) calcd for
C19H15N2O [M + H] 287.1184 found
287.1165.

8-Methyl-3-phenoxy-2-phenylimidazo[1,2-a]pyridine
(7b)
White solid; mp 110–112 °C; Rf = 0.44 (30% ethyl acetate/hexanes);
yield = 168 mg (56%); 1H NMR (400 MHz, CDCl3): δ 8.05 (d, J = 7.3 Hz, 2H), 7.60 (d, J = 6.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 2H),
7.33–7.22 (m, 3H), 7.08 (t, J = 7.4 Hz, 1H),
7.02–6.89 (m, 3H), 6.65 (t, J = 6.8 Hz, 1H),
2.68 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3):
δ 156.4, 140.3, 132.9, 130.7, 130.4, 130.2, 128.7, 127.9, 127.6,
126.7, 123.6, 123.0, 119.5, 115.1, 112.4, 16.5 ppm; IR (KBr) ν
3296, 2637, 1846, 1549, 1120, 998, 660 cm–1; HRMS
(ESI) calcd for C20H17N2O [M + H]
301.1341 found 301.1330.

6-Methyl-3-phenoxy-2-phenylimidazo[1,2-a]pyridine
(7c)
White solid; mp 122–124 °C; Rf = 0.48 (30% ethyl acetate/hexanes);
yield = 174 mg (58%); 1H NMR (400 MHz, CDCl3): δ 8.02 (d, J = 7.3 Hz, 2H), 7.52 (d, J = 9.6 Hz, 2H), 7.42–7.20 (m, 5H), 7.14–7.05
(m, 1H), 7.05–6.99 (m, 1H), 6.95 (d, J = 8.0
Hz, 2H), 2.25 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 156.3, 139.1, 132.8, 131.0, 130.2, 129.9, 128.7, 127.7,
127.6, 126.4, 123.6, 122.2, 119.1, 117.3, 115.1, 18.3 ppm; IR (KBr)
ν 3582, 2922, 1586, 1390, 1264, 1030, 664 cm–1; HRMS (ESI) calcd for C20H17N2O
[M + H] 301.1341 found 301.1324.

3-Phenoxy-2-(p-tolyl)imidazo[1,2-a]pyridine (7d)
Off-white solid; mp 132–134
°C; Rf = 0.44 (30%
ethyl acetate/hexanes); yield = 192 mg (64%); 1H NMR (400
MHz, CDCl3): δ 7.93 (d, J = 7.9
Hz, 2H), 7.73 (d, J = 6.6 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.37–7.27 (m, 2H), 7.24–7.14
(m, 3H),7.09 (t, J = 7.3 Hz, 1H), 6.94 (d, J = 8.0 Hz, 2H), 6.75 (t, J = 6.6 Hz, 1H),
2.34 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3):
δ 156.2, 139.8, 137.7, 131.2, 130.3, 129.8, 129.5, 126.5, 124.5,
123.8, 121.6, 117.8, 115.1, 112.4, 21.4 ppm; IR (KBr) ν 3432,
2751, 1635, 1209, 1156, 979, 679 cm–1; HRMS (ESI)
calcd for C20H17N2O [M + H] 301.1341
found 301.1319.

Supporting Information Available
The Supporting Information
is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.7b00426.1H
and 13C NMR spectra of
all of the products (PDF)

Crystallographic data (ZIP)



Supplementary Material
ao7b00426_si_001.pdf

 ao7b00426_si_002.zip

 Author Contributions
All authors
have given approval to the final version of the manuscript.

The authors
declare no competing financial interest.

Acknowledgments
Vikas
and Ravi thank UGC for the fellowships. We thank SAIF
division CSIR-CDRI for the analytical support. We gratefully acknowledge
financial support by MoES (09-DS/03/2014 PC-IV). CDRI Communication
No. 9496 will be inserted if accepted.
==== Refs
References
Recent reviews on ynamides-

a Wang X.-N. ; Yeom H.-S. ; Fang L.-C. ; He S. ; Ma Z.-X. ; Kedrowski B. L. ; Hsung R. P. 
Acc. Chem. Res. 
2014 , 47 , 560 10.1021/ar400193g .24164363  b Evano G. ; Coste A. ; Jouvin K. 
Angew. Chem., Int.
Ed. 
2010 , 49 , 2840 10.1002/anie.200905817 . c Lu T. ; Hsung R. P. 
Arkivoc 
2014 , 2014 , 127 .26280027  d Nayak S. ; Prabagar B. ; Sahoo A. K. 
Org. Biomol. Chem. 
2016 , 14 , 803 10.1039/C5OB02262B .26612088  e Cook A. M. ; Wolf C. 
Tetrahedron
Lett. 
2015 , 56 , 2377 10.1016/j.tetlet.2015.03.111 .26085692 
a Witulski B. ; Alayrac C. ; Tevzadze-Saeftel L. 
Angew. Chem., Int.
Ed. 
2003 , 42 , 4257 10.1002/anie.200351977 . b Gati W. ; Couty F. ; Boubaker T. ; Rammah M. M. ; Rammah M. B. ; Evano G. 
Org.
Lett. 
2013 , 15 , 3122 10.1021/ol4013298 .23734901  c Gati W. ; Rammah M. M. ; Rammah M. B. ; Evano G. 
Beilstein J. Org. Chem. 
2012 , 8 , 2214 10.3762/bjoc.8.250 .23365632  d Wang Y. ; Song L.-J. ; Zhang X. ; Sun J. 
Angew. Chem., Int. Ed. 
2016 , 55 , 9704 10.1002/anie.201603889 . e Zhang J. ; Zhang Q. ; Xia B. ; Wu J. ; Wang X.-N. ; Chang J. 
Org.
Lett. 
2016 , 18 , 3390 10.1021/acs.orglett.6b01546 .27366955  f Huang H. ; He G. ; Zhu G. ; Zhu X. ; Qiu S. ; Zhu H. 
J. Org. Chem. 
2015 , 80 , 3480 10.1021/acs.joc.5b00071 .25756315  g Huang H. ; Zhu X. ; He G. ; Liu Q. ; Fan J. ; Zhu H. 
Org. Lett. 
2015 , 17 , 2510 10.1021/acs.orglett.5b01045 .25945697 
Recent reviews on imidazopyridines-

a Pires M. J. D. ; Poeira D. L. ; Marques M. M. B. 
Eur. J. Org. Chem. 
2015 , 2015 , 7197 10.1002/ejoc.201500952 . b Bagdi A. K. ; Santra S. ; Monir K. ; Hajra A. 
Chem.
Commun. 
2015 , 51 , 1555 10.1039/C4CC08495K .
Lhassani M. ; Chavignon O. ; Chezal J. M. ; Teulade J. C. ; Chapat J. P. ; Snoeck R. ; Andrei G. ; Balzarini J. ; Clercq E. D. ; Gueiffier A. 
Eur. J. Med. Chem. 
1999 , 34 , 271 10.1016/S0223-5234(99)80061-0 .and the
references cited therein.


a Langer S. Z. ; Arbilla S. ; Benavides J. ; Scatton B. 
Adv. Biochem. Psychopharmacol. 
1990 , 46 , 61 .1981304  b Mizushige K. ; Ueda T. ; Yukiiri K. ; Suzuki H. 
Cardiovasc. Drug Rev. 
2002 , 20 , 163 10.1111/j.1527-3466.2002.tb00085.x .12397365  c Boerner R. J. ; Moller H. J. 
Psychopharmakotherapie 
1997 , 4 , 145 .
Stasyuk A. J. ; Banasiewicz M. ; Cyrański M. K. ; Gryko D. T. 
J. Org. Chem. 
2012 , 77 , 5552 10.1021/jo300643w .22662878 
Yadav J. ; Reddy B. S. ; Rao Y. G. ; Srinivas M. ; Narsaiah A. 
Tetrahedron Lett. 
2007 , 48 , 7717 10.1016/j.tetlet.2007.08.090 .
a Mohan D. C. ; Donthiri R. R. ; Rao S. N. ; Adimurthy S. 
Adv. Synth. Catal. 
2013 , 355 , 2217 10.1002/adsc.201300456 . b Ma L. ; Wang X. ; Yu W. ; Han B. 
Chem. Commun. 
2011 , 47 , 11333 10.1039/c1cc13568f . c Mukhopadhyay S. ; Dighe S. U. ; Kolle S. ; Shukla P. K. ; Batra S. 
Eur. J. Org. Chem. 
2016 , 2016 , 3836 10.1002/ejoc.201600553 . d Lee S. K. ; Park J. K. 
J. Org. Chem. 
2015 , 80 , 3723 10.1021/acs.joc.5b00298 .25742167 
a Yan R. ; Huang G. ; Yan H. ; Yang S. ; Gao X. ; Zhou K. ; Ma C. 
Synlett 
2012 , 23 , 2961 10.1055/s-0032-1317685 . b Santra S. ; Bagdi A. K. ; Majee A. ; Hajra A. 
Adv. Synth. Catal. 
2013 , 355 , 1065 10.1002/adsc.201201112 . c Monir K. ; Bagdi A. K. ; Ghosh M. ; Hajra A. 
Org. Lett. 
2014 , 16 , 4630 10.1021/ol502218u .25140881 
a Talbot E. P. A. ; Richardson M. ; Mckenna J. M. ; Toste F. D. 
Adv. Synth. Catal. 
2014 , 356 , 687 10.1002/adsc.201300996 .24839436  b He C. ; Hao J. ; Xu H. ; Mo Y. ; Liu H. ; Han J. ; Lei A. 
Chem. Commun. 
2012 , 48 , 11073 10.1039/c2cc35927h . c Lei S. ; Chen G. ; Mai Y. ; Chen L. ; Cai H. ; Tan J. ; Cao H. 
Adv. Synth. Catal. 
2015 , 358 , 67 10.1002/adsc.201500803 . d Wang C. ; Lei S. ; Cao H. ; Qiu S. ; Liu J. ; Deng H. ; Yan C. 
J. Org. Chem. 
2015 , 80 , 12725 10.1021/acs.joc.5b02417 .26595127  e Lei S. ; Mai Y. ; Yan C. ; Mao J. ; Cao H. 
Org. Lett. 
2016 , 18 , 3582 10.1021/acs.orglett.6b01588 .27388919  f Cao H. ; Zhan H. ; Lin Y. ; Lin X. ; Du Z. ; Jiang H. 
Org.
Lett. 
2012 , 14 , 1688 10.1021/ol300232a .22417233 
a Li J. ; Neuville L. 
Org. Lett. 
2013 , 15 , 1752 10.1021/ol400560m .23528104  b Wang W. ; Shen Y. ; Meng X. ; Zhao M. ; Chen Y. ; Chen B. 
Org. Lett. 
2011 , 13 , 4514 10.1021/ol201664x .21805970  c Okumura S. ; Takeda Y. ; Kiyokawa K. ; Minakata S. 
Chem. Commun. 
2013 , 49 , 9266 10.1039/c3cc45469j . d He C. ; Hao J. ; Xu H. ; Mo Y. ; Liu H. ; Han J. ; Lei A. 
Chem. Commun. 
2012 , 48 , 11073 10.1039/c2cc35927h . e Liu P. ; Deng C.-L. ; Lei X. ; Lin G.-Q. 
Eur. J. Org. Chem. 
2011 , 2011 , 7308 10.1002/ejoc.201101053 .
Gao Y. ; Yin M. ; Wu W. ; Huang H. ; Jiang H. 
Adv. Synth. Catal. 
2013 , 355 , 2263 10.1002/adsc.201300157 .
Zeng J. ; Tan Y. J. ; Leow M. L. ; Liu X.-W. 
Org. Lett. 
2012 , 14 , 4386 10.1021/ol301858j .22882116 
Garzón M. ; Davies P. W. 
Org. Lett. 
2014 , 16 , 4850 10.1021/ol502346d .25203969 
a Rajesh M. ; Puri S. ; Kant R. ; Reddy M. S. 
Org. Lett. 
2016 , 18 , 4332 10.1021/acs.orglett.6b02077 .27532221  b Kumar G. R. ; Kumar Y. K. ; Reddy M. S. 
Chem. Commun. 
2016 , 52 , 6589 10.1039/C6CC02047J . c Thirupathi N. ; Puri S. ; Reddy T. J. ; Sridhar B. ; Reddy M. S. 
Adv. Synth. Catal. 
2016 , 358 , 303 10.1002/adsc.201500805 . d Kumar R. ; Thorat S. H. ; Reddy M. S. 
Chem. Commun. 
2016 , 52 , 13475 10.1039/C6CC08081B . e Puri S. ; Babu M. H. ; Reddy M. S. 
Org. Biomol. Chem. 
2016 , 14 , 7001 10.1039/C6OB01090C .27355915  f Babu M. H. ; Dwivedi V. ; Kant R. ; Reddy M. S. 
Angew. Chem.,
Int. Ed. 
2015 , 54 , 3783 10.1002/anie.201411261 . g Kumar Y. K. ; Kumar G. R. ; Reddy T. J. ; Sridhar B. ; Reddy M. S. 
Org. Lett. 
2015 , 17 , 2226 10.1021/acs.orglett.5b00832 .25875073  h Rajesh M. ; Thirupathi N. ; Reddy T. J. ; Kanojiya S. ; Reddy M. S. 
J. Org. Chem. 
2015 , 80 , 12311 10.1021/acs.joc.5b02204 .26599200  i Dwivedi V. ; Babu M. H. ; Kant R. ; Reddy M. S. 
Chem. Commun. 
2015 , 51 , 14996 10.1039/C5CC06251A . j Thirupathi N. ; Babu M. H. ; Dwivedi V. ; Kant R ; Reddy M. S. 
Org. Lett. 
2014 , 16 , 2908 10.1021/ol501048x .24819584  k Kumar Y. K. ; Kumar G. R. ; Reddy M. S. 
J. Org. Chem. 
2014 , 79 , 823 10.1021/jo402570t .24344764  l Puri S. ; Thirupathi N. ; Reddy M. S. 
Org. Lett. 
2014 , 16 , 5246 10.1021/ol502224s .25259851  m Thirupathi N. ; Kumar Y. K. ; Kant R. ; Reddy M. S. 
Adv. Synth. Catal. 
2014 , 356 , 1823 10.1002/adsc.201301002 . n Reddy M. S. ; Thirupathi N. ; Babu M. H. ; Puri S. 
J. Org. Chem. 
2013 , 78 , 5878 10.1021/jo400499r .23705802  o Reddy M. S. ; Kumar Y. K. ; Thirupathi N. 
Org. Lett. 
2012 , 14 , 824 10.1021/ol2033493 .22276912 and the references therein.

